AbbVie Inc. $ABBV Stake Boosted by Park Avenue Securities LLC

Park Avenue Securities LLC increased its stake in AbbVie Inc. (NYSE:ABBV) by 5.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 109,857 shares of the company’s stock after purchasing an additional 6,068 shares during the period. Park Avenue Securities LLC’s holdings in AbbVie were worth $25,436,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of AbbVie during the second quarter valued at $4,288,200,000. Laurel Wealth Advisors LLC lifted its position in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in AbbVie by 550.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after purchasing an additional 3,666,521 shares during the last quarter. Vanguard Group Inc. boosted its stake in AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares during the period. Finally, Kingstone Capital Partners Texas LLC bought a new position in AbbVie in the 2nd quarter worth about $581,817,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Up 1.7%

Shares of AbbVie stock opened at $223.88 on Wednesday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market capitalization of $395.69 billion, a PE ratio of 169.61, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The stock’s fifty day moving average is $226.46 and its 200-day moving average is $214.67.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s payout ratio is currently 496.97%.

Analyst Ratings Changes

A number of research firms have recently weighed in on ABBV. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday. Raymond James Financial set a $256.00 target price on AbbVie in a research note on Monday, November 3rd. Scotiabank assumed coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target for the company. JPMorgan Chase & Co. raised their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Finally, Bank of America upped their price objective on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.